Literature DB >> 9086155

Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women.

L Grangeot-Keros1, M J Mayaux, P Lebon, F Freymuth, G Eugene, R Stricker, E Dussaix.   

Abstract

This study assessed the diagnostic value of the cytomegalovirus (CMV)-specific IgG avidity index (AI) for pregnant women without a history of CMV seroconversion. Sera were studied from 40 women with CMV seroconversion (group I), 70 with past CMV infection (group II), 10 (20 sera) with serologic reactivation (group III), and 41 with CMV-specific IgM without proven seroconversion (group IV). Sera from women in group I collected <14 weeks after seroconversion had a low AI (mean, 30% +/- 12%), whereas all sera from women in group II had an AI >60% (mean, 88% +/- 9%). Among the 41 babies born to group IV women, only 4 were infected with CMV (all born to mothers with a low [<30%] AI early in pregnancy). These results suggest that AI determination may help to date a primary CMV infection in pregnant women who lack seroconversion history.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086155     DOI: 10.1086/513996

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  54 in total

1.  A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.

Authors:  M H Korhonen; J Brunstein; H Haario; A Katnikov; R Rescaldani; K Hedman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection.

Authors:  M J Sipewa; P Goubau; M Bodéus
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  Use of four dengue virus antigens for determination of dengue immune status by enzyme-linked immunosorbent assay of immunoglobulin G avidity.

Authors:  Séverine Matheus; Xavier Deparis; Bhety Labeau; Josiane Lelarge; Jacques Morvan; Philippe Dussart
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

5.  Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample.

Authors:  Séverine Matheus; Xavier Deparis; Bhety Labeau; Josiane Lelarge; Jacques Morvan; Philippe Dussart
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Distinguishing primary CMV infection from reactivation of latent infection.

Authors:  Venkataraman Subramanian
Journal:  Dig Dis Sci       Date:  2007-05-09       Impact factor: 3.199

7.  Measurement of the sensitivity of different commercial assays in the diagnosis of CMV infection in pregnancy.

Authors:  M Gentile; C Galli; P Pagnotti; P Di Marco; S Tzantzoglou; F Bellomi; M L Ferreri; C Selvaggi; G Antonelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-10       Impact factor: 3.267

8.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Cytomegalovirus Infection in Pregnancy - Counselling Challenges in the Setting of Generalised Testing.

Authors:  Anca Maria Ciobanu; Nicolae Gica; Corina Gica; Radu Botezatu; Mirona Furtuna; Gheorghe Peltecu; Anca Maria Panaitescu
Journal:  Maedica (Bucur)       Date:  2020-06

10.  Clinical evaluation of a chemiluminescence immunoassay for determination of immunoglobulin g avidity to human cytomegalovirus.

Authors:  Maria Grazia Revello; Giovanna Gorini; Giuseppe Gerna
Journal:  Clin Diagn Lab Immunol       Date:  2004-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.